Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 22

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 22
---
 Today, September 13, 2025 at 36. 3. Source: Roger Zaldivar, "Phakic IOL for Low Myopia," ESCRS Congress proceedings, Copenhagen, Denmark, September 2025. ▪ Published data demonstrate that ICL patients experience improved visual acuity across the full range of myopia compared with their prior corrective solution 1 ▪ Many LASIK patients experience visual regression of 1 diopter or more over 10 years 2 — In contrast, phakic IOLs (like STAAR’s EVO ICL) are not associated with visual regression 2 — This suggests that phakic IOLs are superior to laser refractive surgery, particularly as no corneal aberration is induced ▪ Recent application of clinical AI technology is making it far easier for surgeons to match patients with their optimal EVO ICL lens; as more surgeons adopt AI technologies, the EVO ICL’s market share is likely to continue to increase, in our view — In fact, one leading surgeon recently predicted that ICLs “will become the standard of care in vision correction procedures [over] the next five years” 3 4 Data from a recent study indicate that ICL surgery is associated with a significant gain in best - corrected visual acuity, meaning that many patients see better than they did with glasses or contacts 1 B

Broadwood Partners, L.P. 11% 29% (10%) 14% 2010-2019 2019-2023 2023-2025P 2025P-2030P Historical Growth Rate Pandemic-Related Improvement Short-Term Tactical Challenges Return to Consistent Growth 6% 19% 9% 27% 2010-2019 2019-2023 2023-2025P 2025P-2030P Historical Margin¹ Pandemic-Related Improvement¹ Short-Term Tactical Challenges Accelerating Profitability Net Sales CAGR Average Adjusted EBITDA Margin Management Is Forecasting a Quick Return to Growth and Profitability… 31 Source: Historical data from FactSet and STAAR Annual Reports on Form 10 - K for the applicable fiscal years. Projections from STA AR proxy statement on Form DEFM14A, filed with the SEC on September 16, 2025 at 61. 1. 2010 - 2021 Adjusted EBITDA estimated based on EBITDA as calculated by FactSet